Cauza Edmund, Spak Marita, Cauza Karla, Hanusch-Enserer Ursula, Dunky Attila, Wagner Ernst
Department of Internal Medicine V, Department of Rheumatology, Wilhelminenspital, Montleartstrasse 37, 1160 Vienna, Austria.
Rheumatol Int. 2002 Nov;22(6):227-32. doi: 10.1007/s00296-002-0246-3. Epub 2002 Sep 4.
The aim was to evaluate the efficacy and safety of multiple infusions with achimeric, anti-tumor necrosis factor (TNF)alpha monoclonal antibody (infliximab) in patients with psoriatic arthritis (PsA) and psoriasis vulgaris.
Over 22 weeks, nine patients with both active psoriasis and PsA received five infusions of 3 mg/kg infliximab. The endpoints included changes in the swollen and tender joints counts, American College of Rheumatology (ACR) preliminary criteria for improvement response rates 20, 50, and 70, and improvement in the psoriasis area and severity index (PASI).
The swollen count (SJC) and tender joint count (TJC) fell from means of 5.33+/-2.22 and 17.80+/-4.21 to 1.44+/-1.09 and 9.77+/-0.92, respectively, by week 2 ( P=0.02, P=0.02). This benefit was sustained through week 22 (2.00+/-1.12/7.77+/-3.68, P=0.05/ P=0.002). The ACR 20/50/70 response was achieved in 89%/56%/22% of cases. The mean PASI score improved from 19.04+/-5.41 to 4.91+/-2.51 ( P=0.002).
Multiple infusions of infliximab were effective and well tolerated in patients with active psoriasis and PsA.
评估嵌合型抗肿瘤坏死因子（TNF）α单克隆抗体（英夫利昔单抗）多次输注治疗银屑病关节炎（PsA）和寻常型银屑病患者的疗效和安全性。
在22周内，9例同时患有活动性银屑病和PsA的患者接受了5次3mg/kg英夫利昔单抗输注。观察终点包括肿胀和压痛关节计数的变化、美国风湿病学会（ACR）改善反应率20、50和70的初步标准，以及银屑病面积和严重程度指数（PASI）的改善情况。
到第2周时，肿胀关节计数（SJC）和压痛关节计数（TJC）分别从均值5.33±2.22和17.80±4.21降至均值1.44±1.09和9.77±0.92（P = 0.02，P = 0.02）。这种益处持续到第22周（2.00±1.12/7.77±3.68，P = 0.05/P = 0.002）。89%/56%/22%的病例达到了ACR 20/50/70反应。PASI平均评分从19.04±5.41改善至4.91±2.51（P = 0.002）。
多次输注英夫利昔单抗对活动性银屑病和PsA患者有效且耐受性良好。
